» Articles » PMID: 29261779

Median Regression Spline Modeling of Longitudinal FEV1 Measurements in Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) Patients

Overview
Journal PLoS One
Date 2017 Dec 21
PMID 29261779
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Clinical phenotyping, therapeutic investigations as well as genomic, airway secretion metabolomic and metagenomic investigations can benefit from robust, nonlinear modeling of FEV1 in individual subjects. We demonstrate the utility of measuring FEV1 dynamics in representative cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) populations.

Methods: Individual FEV1 data from CF and COPD subjects were modeled by estimating median regression splines and their predicted first and second derivatives. Classes were created from variables that capture the dynamics of these curves in both cohorts.

Results: Nine FEV1 dynamic variables were identified from the splines and their predicted derivatives in individuals with CF (n = 177) and COPD (n = 374). Three FEV1 dynamic classes (i.e. stable, intermediate and hypervariable) were generated and described using these variables from both cohorts. In the CF cohort, the FEV1 hypervariable class (HV) was associated with a clinically unstable, female-dominated phenotypes while stable FEV1 class (S) individuals were highly associated with the male-dominated milder clinical phenotype. In the COPD cohort, associations were found between the FEV1 dynamic classes, the COPD GOLD grades, with exacerbation frequency and symptoms.

Conclusion: Nonlinear modeling of FEV1 with splines provides new insights and is useful in characterizing CF and COPD clinical phenotypes.

Citing Articles

Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.

Silveira C, Cobian-Guemes A, Uranga C, Baker J, Edlund A, Rohwer F Int J Mol Sci. 2021; 22(21).

PMID: 34769481 PMC: 8584531. DOI: 10.3390/ijms222112050.


New Insights in Microbial Species Predicting Lung Function Decline in CF: Lessons from the MucoFong Project.

Francis F, Enaud R, Soret P, Lussac-Sorton F, Avalos-Fernandez M, MucoFong Investigation Group J Clin Med. 2021; 10(16).

PMID: 34442021 PMC: 8396880. DOI: 10.3390/jcm10163725.


Cystic Fibrosis Rapid Response: Translating Multi-omics Data into Clinically Relevant Information.

Cobian Guemes A, Lim Y, Quinn R, Conrad D, Benler S, Maughan H mBio. 2019; 10(2).

PMID: 30992350 PMC: 6469968. DOI: 10.1128/mBio.00431-19.

References
1.
Exuzides A, Colby C, Briggs A, Lomas D, Molken M, Tabberer M . Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. Med Decis Making. 2015; 37(4):453-468. DOI: 10.1177/0272989X15610781. View

2.
Hankinson J, Odencrantz J, Fedan K . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999; 159(1):179-87. DOI: 10.1164/ajrccm.159.1.9712108. View

3.
Aarli B, Calverley P, Jensen R, Eagan T, Bakke P, Hardie J . Variability of within-breath reactance in COPD patients and its association with dyspnoea. Eur Respir J. 2014; 45(3):625-34. DOI: 10.1183/09031936.00051214. View

4.
Casanova C, Aguirre-Jaime A, de Torres J, Pinto-Plata V, Baz R, Marin J . Longitudinal assessment in COPD patients: multidimensional variability and outcomes. Eur Respir J. 2013; 43(3):745-53. DOI: 10.1183/09031936.00096913. View

5.
Szczesniak R, McPhail G, Duan L, Macaluso M, Amin R, Clancy J . A semiparametric approach to estimate rapid lung function decline in cystic fibrosis. Ann Epidemiol. 2013; 23(12):771-7. DOI: 10.1016/j.annepidem.2013.08.009. View